The FDA almost never reveals its thinking about a drug prior to issuing a regulatory decision, and when that decision is a rejection the letter to the company is always confidential. Brainstorm Cell ...
NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival ...
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entered ...
BrainStorm Cell Therapeutics is mapping out the path forward for its experimental amyotrophic lateral sclerosis (ALS) therapy, and while those plans include a new Phase 3 clinical trial, the biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results